Rotem Industries - Medical Imaging
Gil Groer is an accomplished executive with extensive experience in the medical, defense, and logistics industries. Currently serving as Chief Executive Officer at Rotem Industries since August 2021, Gil Groer also holds the position of Board Member for global companies in the USA and Germany. Previously, Gil Groer led Danlog Intercosma Ltd. as Chief Executive Officer from 2013 to August 2021, managing significant financial operations with a budget of 150 million Shekels and overseeing 500 employees. Prior experience includes a role as Vice President Finance at Extra Plastic Group from 1995 to 2013, where Gil Groer was influential in strategic initiatives and co-established a manufacturing site in Romania. Academic credentials include a Bachelor's degree in Accounting and Business Management from The College of Management Academic Studies.
This person is not in the org chart
This person is not in any teams
Rotem Industries - Medical Imaging
Hi-tech company specializing in the development and commercialization of technologies from research centers and start-ups. Rotem markets its products worldwide and has subsidiaries in the USA and Germany. Main business areas are medical imaging, crystal manufacturing, radiation detection and renewable energy. Rotem Industries' Medical Imaging business is a world leader in consumables for PET imaging. Rotem develops, manufactures and supplies complete packages for the production of radiotracers: oxygen-18 enriched water, plastic cassettes, precursors and complete reagent kits for a range of synthesis modules. Rotem serves its customers through a global distribution network, and Rotem excels in uncompromising product quality coupled with a deep understanding of customer needs to ensure uniformly high production yields and unsurpassed quality. The passion for quality is driven by a team of highly skilled and dedicated professionals who recognize the critical role their products play in the PET radiotracer production chain. Rotem is very active in the development and production of consumables for new radiotracers under development. These projects benefit from our interdisciplinary expertise and direct market access, which is the result of years of direct, day-to-day, close collaboration with radiopharmaceutical companies worldwide.